Prosecution Insights
Last updated: October 26, 2026

Matthew P Coughlin, USPTO Patent Examiner

Listed by the USPTO as COUGHLIN, MATTHEW P

Tech Center 1600 • Art Units: 1626 1691

This examiner grants 71% of resolved cases

Analysis

COUGHLIN, MATTHEW P handles matters in Tech Center 1600 and Art Unit 1626. The profile covers 1007 resolved cases, with a 71.3% allowance rate and an 891-day median to allowance. Interviews show a 12.5% lift, making them a targeted option when direct discussion can clarify the issues raised in a written action.

The listed companies are University of Florida Research Foundation Inc., Hoffmann-La Roche Inc., and Novartis AG. The listed firms are BALLARD SPAHR LLP, BakerHostetler, and BIRCH STEWART KOLASCH & BIRCH, LLP. The figures support portfolio planning around allowance expectations, response timing, and selective interview use.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

71.3%
Allow Rate
+11.3% vs TC avg
1,064
Total Applications
+12.5%
Interview Lift
891
Avg Prosecution Days
Based on 1007 resolved cases, 2023–2026

Rejection Statute Breakdown

2.7%
§101 Eligibility
18.9%
§102 Novelty
24.2%
§103 Obviousness
32.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16772768 SUBSTITUTED AROMATIC AMINES FOR USE IN ORGANIC ELECTROLUMINESCENT DEVICES Non-Final OA Merck Patent GmbH
18363004 ANTIMICROBIAL COMPOSITION COMPRISING A DIOCTYLDIMETHYLAMMONIUM COMPOUND Non-Final OA The Procter & Gamble Company
18626788 PROCESS FOR PREPARING SUBSTITUTED CYCLOHEXANE AMINO ACID ESTERS AND SPIROKETAL-SUBSTITUTED CYCLIC KETO-ENOLS Non-Final OA Bayer Aktiengesellschaft
18274293 COMPOSITIONS AND METHODS FOR INHIBITING YAP Non-Final OA The United States Government as represented by the Department of Veterans Affairs
18036095 PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES Final Rejection Icahn School of Medicine at Mount Sinai
18030935 Antibacterial And Deodorizing Composition, And Preparation Method Therefor Non-Final OA LG Chem, Ltd.
18325264 PROCESS FOR PRODUCING FURFURAL FROM BIOMASS Final Rejection UOP LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Matthew P Coughlin's allowance rate?

71.3% of resolved applications examined by Matthew P Coughlin were allowed (1,007 resolved cases), compared with 54.9% across Art Unit 1626 over the last five years.

Does an interview help with examiner Matthew P Coughlin?

This examiner's interview lift is +12.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Matthew P Coughlin take to allow a patent?

Applications allowed by Matthew P Coughlin took 891 days on average from filing to allowance.

Which art unit does examiner Matthew P Coughlin work in?

Matthew P Coughlin examines applications in Art Unit 1626 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month